Contract 75A50118C00024
Mapp Biopharmaceutical, Inc. · Department Of Health And Human Services · September 1, 2021
Mapp Biopharmaceutical, Inc. was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on September 1, 2021 for $970,000 of work in research and development in the physical, engineering, and life sciences (except nanotechnology and biotechnology). Performance is in San Diego, CA. It was awarded under full and open competition. The contract has been modified 2 times since the base award It uses cost-plus contract pricing. The most recent modification was on August 7, 2024. If all options are exercised, the contract could reach $62.51 million.
Contract details
- PIID
- 75A50118C00024
- Award type
- Definitive Contract
- Pricing
- Cost Plus Fixed Fee
- Set-aside
- No Set Aside Used.
- Competition
- Full And Open Competition
- NAICS
- 541715 · Research And Development In The Physical, Engineering, And Life Sciences (Except Nanotechnology And Biotechnology)
- Product / service
- Health R&D Services; Health Care Services; Experimental Development
- Place of performance
- San Diego, CA
- First action
- September 1, 2021
- Latest action
- August 7, 2024
Description
ADVANCE MBP134, A COCKTAIL OF TWO HUMAN MONOCLONAL ANTIBODIES (MBP047 AND MBP087), AS A POTENTIAL MEDICAL COUNTERMEASURE TO TREAT ACTIVE INFECTIONS OF SUDAN VIRUS - UPDATE INDIRECT RATES LETTER
Modification timeline
-
August 7, 2024Mod P00023 · Supplemental Agreement For Work Within Scope$56.70M
-
September 28, 2022Mod P00013 · Other Administrative ActionADVANCE MBP134, A COCKTAIL OF TWO HUMAN MONOCLONAL ANTIBODIES (MBP047 AND MBP087), AS A POTENTIAL MEDICAL COUNTERMEASURE TO TREAT ACTIVE INFECTIONS OF SUDAN VIRUS$55.84M
-
September 1, 2021Mod P00005 · Supplemental Agreement For Work Within ScopeREVISE STATEMENT OF WORK; AND PROVIDE SUPPLEMENTAL FUNDING$40.30M
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| The Emmes Company, Llc | Department Of Health And Human Services | April 1, 2026 | $771.5K |
| Leidos Biomedical Research Inc | Department Of Health And Human Services | April 1, 2026 | $8.00M |
| Leidos Biomedical Research Inc | Department Of Health And Human Services | April 1, 2026 | $9.22M |
| Leidos Biomedical Research Inc | Department Of Health And Human Services | April 1, 2026 | $327.13M |
| The Brain Donor Project, Inc | Department Of Health And Human Services | April 1, 2026 | $1.27M |
| Leidos Biomedical Research Inc | Department Of Health And Human Services | April 1, 2026 | $20.43M |
Top contractors in NAICS 541715
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Fluor Marine Propulsion, Llc | 2 | $2.75B |
| 2 | California Institute Of Technology | 240 | $979.40M |
| 3 | The Johns Hopkins University Applied Physics Laboratory Llc | 204 | $482.74M |
| 4 | Lockheed Martin Corporation | 4 | $461.91M |
| 5 | Lockheed Martin Corp | 9 | $317.27M |
| 6 | The Aerospace Corporation | 85 | $308.18M |
| 7 | Fermi Forward Discovery Group, Llc | 1 | $289.92M |
| 8 | Lockheed Martin Corp | 7 | $285.45M |
| 9 | Amentum Technology, Inc. | 4 | $253.24M |
| 10 | The Mitre Corporation | 50 | $222.51M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 75A50118C00024?
Contract 75A50118C00024 is a federal contract awarded to Mapp Biopharmaceutical, Inc. by Department Of Health And Human Services on September 1, 2021 for $970,000 of work classified under RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY). It has been modified 2 times since the base award.
Who won contract 75A50118C00024?
Mapp Biopharmaceutical, Inc. won contract 75A50118C00024 from Department Of Health And Human Services.
How much is contract 75A50118C00024 worth?
Contract 75A50118C00024 has obligated $970,000 to date, with a total potential value of $62.51 million if all options are exercised.